Well Pigs never answered my question of what is a better value biotech on the ASX than CUV right now. So below is a comparison chart from the last half yearly figures compared to Current Market Cap.s. The figures are a bit dated but it must be remembered that even though CUV is a standout on those figures it is the much weaker half for CUV, this current half yearly will be much stronger and will emphasise just how well CUV is doing compared to all other biotechs. Furthermore in recent months CUV has started STROKE trials, gained Israel market access, expanded US rollout and advanced the DNA repair program. PME has slightly stronger financials but is four times greater valuation. The standout is clear.
All IMO DYOR
Ann: Media release - First stroke patient with afamelanotide, page-35
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.28 |
Change
-0.250(1.85%) |
Mkt cap ! $664.8M | |||
| Open | High | Low | Value | Volume |
| $13.55 | $13.62 | $13.25 | $1.157M | 86.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 227 | $13.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.42 | 228 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |